TCRX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-12

• We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with …

• In June 2026, we provided an update on our hematologic (heme) malignancies clinical program, including initial data from Cohort C of our ongoing Phase 1 ALLOHA™ trial evaluating TSC-101, generated with our commercial-ready manufacturing process, in patients with heme malignancies undergoing allogene…

• We are further expanding our heme malignancies program with the addition of TCRs targeting other HLA types. TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45. Like TSC-101, these candidates are designed to eliminate residual cance…

• In accordance with generally accepted accounting principles, we evaluated whether conditions and events, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern for twelve months after the date these condensed consolidated financial statements are issued…

• Based on our current operating plan, existing cash and cash equivalents are expected to fund operations into the second quarter of 2027, but are not expected to be sufficient to fund our obligations for at least twelve months after the issuance date of these condensed consolidated financial statemen…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with …

• We are further expanding our hematologic (heme) malignancies program with the addition of TCRs targeting other HLA types. TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes derived from CD45. Like TSC-101, these candidates are designed to eliminate …

• We believe that our existing cash and cash equivalents will enable us to fund our current operating plan into the second half of 2027. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. For additional inf…

• The following table summarizes our results of operations for the three months ended March 31, 2026 and 2025 (in thousands):

• Revenue for the first quarter of 2026 was $1.0 million, compared to $2.2 million for the first quarter of 2025. The decrease was primarily due to the timing of research activities performed pursuant to our collaboration agreement with Amgen which commenced in May 2023.

Text added vs the prior filing · source: 10-Q · 2026-08-12

• *We have identified conditions that raise substantial doubt about our ability to continue as a going concern.

• Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Quarterly Report on Form 10-Q, and we will need to obtain additional funding. We may be forced to delay or reduce the sc…

• policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them…

• Our operations consume substantial amounts of cash, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new products, retain or expand our current levels of personnel, support our programs, enhance our ope…

• On November 3, 2025, the Company announced a prioritization strategy and pursuant to this strategy, the Company also implemented a workforce reduction of approximately 30%, or 66 roles. The workforce reduction has resulted in the loss of longer-term employees, the loss of certain institutional knowl…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• we raise additional capital pursuant to collaborations, licensing arrangements or other strategic partnerships, such agreements may require us to relinquish rights to our technologies or product candidates.

• Our operations consume substantial amounts of cash, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new products, retain or expand our current levels of personnel,

• support our programs, enhance our operating infrastructure, and potentially acquire complementary businesses and technologies. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:

• On November 3, 2025, the Company announced a prioritization strategy and pursuant to this strategy, the Company also implemented a workforce reduction of approximately 30%, or 66 roles. The workforce reduction that will accompany our prioritization strategy will result in the loss of longer-term emp…

• We, and any third-party contract manufacturers we engage to support our clinical trials, may experience manufacturing difficulties due to limited manufacturing experience, resource constraints or as a result of labor disputes, geopolitical and economic tensions with China, including as a result of t…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5- 1(c)

• Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to the terms of the trading plan

• Trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5- 1(c)

• Exercises of vested stock options and sales of shares of the Company’s common stock pursuant to the terms of the trading plan

• Other than as disclosed above, no other officer or director adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K) during the three months ended March 31, 2026.